Current Report Filing (8-k)
November 16 2017 - 4:06PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): November 9, 2017
MARRONE
BIO INNOVATIONS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-36030
|
|
20-5137161
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
1540
Drew Avenue, Davis, CA
|
|
95618
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (530) 750-2800
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
On
November 9, 2017, Michael Benoff and Kathleen Merrigan, Ph.D., currently Class I directors of Marrone Bio Innovations, Inc. (the
“Company”), notified the Company that they have decided not to stand for re-election to the Company’s board
of directors (the “Board”) at the Company’s 2017 annual meeting of stockholders (the “Annual Meeting”).
Mr. Benoff and Dr. Merrigan expect to continue to serve as members of the Board until the Annual Meeting, including their service
on the Compensation Committee, Audit Committee and the Nominating and Corporate Governance Committee. Mr. Benoff and Dr. Merrigan’s
respective decisions not to stand for re-election were for personal reasons and time considerations and did not involve any disagreement
on any matter relating to the Company’s operations, policies or practices.
The
Board has determined to include one director nominee for election at the Annual Meeting in the Company’s forthcoming proxy
statement, and that effective upon the commencement of the Annual Meeting, the size of the Board will be reduced to five and the
number of Class I directors will be reduced to one.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
MARRONE
BIO INNOVATIONS, INC.
|
|
|
|
Dated:
November 16, 2017
|
By:
|
/s/
Linda V. Moore
|
|
|
Linda
V. Moore
|
|
|
Executive
Vice President, General Counsel and Secretary
|
Marrone Bio Innovations (NASDAQ:MBII)
Historical Stock Chart
From Mar 2024 to Apr 2024
Marrone Bio Innovations (NASDAQ:MBII)
Historical Stock Chart
From Apr 2023 to Apr 2024